In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intersect Follows Leaders In ENT

Executive Summary

Following the lead of ENT start-ups like Acclarent and Entellus Medical, Intersect ENT Inc. is introducing a line of stent like implants capable of performing the same role drug-eluting stents played in interventional cardiology. Intersect’s implants provide moderate structural support to tissue that has been cut or dilated through FESS or balloon sinuplasty. But the principal function of the implant isn’t propping open nasal passageways but rather delivering drugs. A trio of clinical studies conducted by the company has found the released steroids produced statistically significant reductions in inflammation, polyp formation, and postoperative adhesions.

You may also be interested in...



People Briefs: Owens & Minor, Laurimed, Xagenic, Intersect ENT

Owens & Minor launched a search to replace its retiring CEO; Laurimed named its new CEO; Xagenic hired a VP of product development; and Intersect ENT appointed a chief commercial officer.

Research Briefs: Data From Intersect ENT, BioVentrix and Hologic

Encouraging pilot trial results on a drug-eluting implant for sinusitis made by Intersect ENT. First-in-man procedure with myocardial anchoring system for heart failure from BioVentrix. Final analysis of registry data confirms the efficacy of Hologic’s MammoSite breast brachytherapy system.

Acclarent’s Balloon Sinuplasty Device Relieva Heads To Asian Clinics

Johnson & Johnson subsidiary Acclarent demonstrated its hand-held Relieva sinuplasty technology with its first in-office demonstration procedure in Malaysia, seeking to highlight the minimally invasive procedure for sinusitis as the company starts a push in Asia.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel